Sangamo Therapeutics, Inc.

NasdaqCM:SGMO Stock Report

Market Cap: US$515.4m

Sangamo Therapeutics Future Growth

Future criteria checks 2/6

Sangamo Therapeutics is forecast to grow earnings and revenue by 63.2% and 39.7% per annum respectively while EPS is expected to grow by 61.7% per annum.

Key information

63.2%

Earnings growth rate

61.7%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate39.7%
Future return on equityn/a
Analyst coverage

Good

Last updated13 Dec 2024

Recent future growth updates

Recent updates

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%

Dec 08
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

Nov 20
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Oct 23
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?

Oct 21

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09
We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04
Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11
Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Aug 15
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Aug 08
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

May 30
Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

May 13
Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Apr 11
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Dec 20
We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Sep 22

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sep 18
Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Aug 31

Sangamo Therapeutics: Cheap, But Justifiably So

Aug 09

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

May 08
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Apr 11
Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Sangamo Therapeutics: Lost In Transition From Lab To Clinic

Feb 24

Earnings and Revenue Growth Forecasts

NasdaqCM:SGMO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202699-5349596
12/31/202596-43-28-187
12/31/202459-97-93-906
9/30/202452-135-117-114N/A
6/30/202412-248-179-173N/A
3/31/202419-328-218-207N/A
12/31/2023176-258-246-225N/A
9/30/2023201-250-257-231N/A
6/30/2023218-199-265-238N/A
3/31/2023241-127-258-231N/A
12/31/2022111-192-244-224N/A
9/30/2022112-178-235-219N/A
6/30/2022114-172-241-225N/A
3/31/2022113-176-242-224N/A
12/31/2021111-178-257-233N/A
9/30/2021109-181-209-185N/A
6/30/2021138-135-116-92N/A
3/31/2021131-124101120N/A
12/31/2020118-121155170N/A
9/30/2020147-76136153N/A
6/30/2020111-1026481N/A
3/31/2020107-96-137-118N/A
12/31/2019102-95-165-144N/A
9/30/201974-118-206-164N/A
6/30/201976-104-200-152N/A
3/31/201980-90-3710N/A
12/31/201884-68-737N/A
9/30/201871-634460N/A
6/30/201859-62N/A72N/A
3/31/201846-58N/A6N/A
12/31/201737-55N/A11N/A
9/30/201732-51N/A16N/A
6/30/201723-58N/A14N/A
3/31/201719-72N/A-59N/A
12/31/201619-72N/A-66N/A
9/30/201620-76N/A-63N/A
6/30/201625-66N/A-60N/A
3/31/201630-52N/A-52N/A
12/31/201540-41N/A-34N/A
9/30/201545-31N/A-27N/A
6/30/201549-29N/A-19N/A
3/31/201551-24N/A-19N/A
12/31/201446-26N/A-6N/A
9/30/201438-30N/A-5N/A
6/30/201431-29N/A-3N/A
3/31/201428-27N/A0N/A
12/31/201324-27N/A-19N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGMO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGMO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGMO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGMO's revenue (39.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: SGMO's revenue (39.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SGMO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangamo Therapeutics, Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gregory HarrisonBofA Global Research
Jonathan AschoffBrean Capital